CMG Pharmaceutical plans a 10-for-1 reverse stock split after South Korea's new penny-stock delisting regime swept the company and four other pharmaceutical and biotech names into a group of 36 listed firms designated for administrative management. The July 1 rules added a 1,000 won minimum share-price test and raised minimum market capitalization thresholds to 30 billion won for KOSPI companies and 20 billion won for KOSDAQ companies, prompting complaints that innovative businesses can be penalized even when they hold substantial assets or approved drugs. CMG, whose schizophrenia treatment was identified in an earlier company statement as Mezopi and in the broader report as Mezofy, said shareholders will vote on September 2, 2026 on consolidating ten 500-won shares into one 5,000-won share; if approved, trading will be suspended from October 1 through October 26 and the new shares will list on October 27. The company said the move followed 30 consecutive trading days below 1,000 won, while the broader report said its stock ranged from 609 won to 986 won over that period and valued the company at 99.4 billion won on Thursday. CMG has also said it aims to rebuild value through R&D, new products, orally dissolving film medicines and U.S. commercialization talks for its FDA-approved schizophrenia treatment.